About 5.7 million people in the United States have heart failure, which occurs when the heart cannot pump enough blood and oxygen to support other organs in the body. Heart failure is a chronic disease, however, with treatment, signs, and symptoms can improve. To ensure each patient receives the right treatment at the right time, a team at Penn Medicine launched a project in which they are using a set of fatty acid metabolites called acylcarnitines as biomarkers to differentiate heart failure patients. By combining acylcarnitines with clinical-based parameters, the team developed algorithms to track and accurately predict which patients may progress rapidly in their disease courses. The information will enable clinicians to tailor decisions on the timing of pharmaceutical treatment or advanced surgical therapies, such as left-ventricular-assisted-device placement or heart transplant. Learn more about this Precision Medicine project:
Learn More About Doctor Wang:
#HeartFailure #PrecisionMedicine #PennMedicine
0 Comments